Information for the public

What has NICE said?

Ombitasvir–paritaprevir–ritonavir (Viekirax) with or without dasabuvir (Exviera) is recommended as a possible treatment for adults with some types (called genotypes) of chronic hepatitis C. It is sometimes taken with ribavirin. See table 1.

Table 1 Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for adults with chronic hepatitis C

Type of hepatitis C

Treatment recommended by NICE

Length of treatment

1a, without cirrhosis

Ombitasvir–paritaprevir–ritonavir with dasabuvir and ribavirin

12 weeks

1a, with cirrhosis

Ombitasvir–paritaprevir–ritonavir with dasabuvir and ribavirin

24 weeks

1b, without cirrhosis

Ombitasvir–paritaprevir–ritonavir with dasabuvir

12 weeks

1b, with cirrhosis

Ombitasvir–paritaprevir–ritonavir with dasabuvir and ribavirin

12 weeks

4, without cirrhosis

Ombitasvir–paritaprevir–ritonavir with ribavirin

12 weeks

4, with cirrhosis

Ombitasvir–paritaprevir–ritonavir with ribavirin

24 weeks

What does this mean for me?

If you have genotype 1 or 4 chronic hepatitis C, and your healthcare team think that ombitasvir–paritaprevir–ritonavir with or without dasabuvir is the right treatment, you should be able to have the treatment on the NHS.

The treatment should be available on the NHS within 3 months of the guidance being issued.

  • Information Standard